| Literature DB >> 29401500 |
Michael D Shields1, Fahad ALQahtani2, Michael P Rivey2,3, James C McElnay2.
Abstract
We describe, for the first time, the use of a mobile device platform for remote direct observation of inhaler use and technique. The research programme commenced with a rapid systematic review of mobile device (or videophone) use for direct observation of therapy (MDOT). Ten studies (mainly pilots) were identified involving patients with tuberculosis, sickle cell disease and Alzheimer's disease. New studies are ongoing (ClinicalTrials.gov website) in TB, stroke, sickle cell disease, HIV and opioid dependence. Having identified no prior use of MDOT in inhaler monitoring, we implemented a feasibility study in 12 healthy volunteer children (2-12 years; 8 females and 4 males) over a period of 14 days, with twice daily video upload of their 'dummy' inhaler use. Two children uploaded 100% of the requested videos, with only one child having an inhaler upload rate of <75%. The quality of uploaded videos was generally good (only 1.7% of unacceptable quality for evaluation). The final aspect of the research was a pilot study using MDOT (6 weeks) in 22 children with difficult to treat asthma. Healthcare professionals evaluated inhaler technique using uploaded videos and provided telephone instruction on improving inhaler use. The main outcomes were assessed at week 12 post initiation of MDOT. By week 5, all children still engaging in MDOT (n = 18) were judged to have effective inhaler technique. Spirometry values did not vary to a significantly significant degree between baseline and 12 weeks (P>0.05), however, mean fraction of exhaled nitric oxide (FeNO) values normalised (mean 38.7 to 19.3ppm) and mean Asthma Control Test values improved (13.1 to mean 17.8). Feedback from participants was positive. Overall the findings open up a new paradigm in device independent (can be used for any type of inhaler device) monitoring, providing a platform for evaluating / improving inhaler use at home.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29401500 PMCID: PMC5798760 DOI: 10.1371/journal.pone.0190031
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study extraction and selection process in rapid systematic review (RSR).
Summary of the characteristics of the study included in the rapid systematic review (RSR).
| Author, Year, Country | Title and Journal | Device used for recording video of treatment and study duration | Method: | Aim of study | Findings | Conclusions |
|---|---|---|---|---|---|---|
| Garfein | Feasibility of tuberculosis treatment monitoring by video directly observed therapy: a Binational pilot study | Smartphone. | Pilot study recruited 52 patients (18–86 years) from San Deigo (US) and Tijuana (Mexico). Recorded video of treatment administration and submitted to be seen by health worker. | To investigate, using videophone recording, adherence to TB treatment in two countries, US and Mexico. Also, examined the extent of patient satisfaction. | The adherence rate was comparable in the two nations; 90% (San Deigo) and 96% (Tijuana). Mobile use in this study was highly acceptable. | Video directly observed therapy is a satisfactory approach and can be used to assess adherence in rich or poor resource countries. |
| Mirsaeidi | Video directly observed therapy for treatment of tuberculosis is patient-oriented and cost-effective. | Mobile phone or laptop. The majority of participants used this approach up to 4 months (64%) while 24% used it up to 8 months. | Retrospective study; 20 patients used DOT method and were compared with 11 patients who used videophone assessed DOT (19–64 years old). | Assessment of the cost effectiveness of observation and the level of satisfaction with the videophone DOT approach. | All videophone patients (n = 11) completed the study. 9 patients used a mobile phone or a laptop for observation. | Observation via mobile phone was feasible and had a high tendency to improve adherence and save costs. |
| Creary | A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in paediatric patients with sickle-cell disease. | Smartphone or computer. | Electronic observed therapy method was used to measure adherence of hydroxyurea in 15 patients (1–22 years) with sickle cell disorder. | To study the feasibility of electronic adherence monitoring of hydroxylurea in children via recording treatment using mobile phone application or computer. | Fourteen children completed the pilot study. The median of treatment adherence was 93.3%. The approach had a high rate of acceptance. | Recording medicine taking via electronic device was feasible, highly acceptable and could be utilised to promote adherence. |
| Gassanov | The use of videophone for directly observed therapy for the treatment of tuberculosis | Video phone. The trial duration was five weeks. | Pilot study involved 13 patients who successfully adhered to DOT at clinic. Patients supplied with a video enabled telephone to use at home, with network connection to clinic for observation remotely. | To evaluate video DOT flexibility in the delivery of video enabled DOT method at home. | Videophone was convenient and had flexibility for observation. The rate of adherence for patients attending clinic (DOT) method (98%) was comparable to patients using videophone method at home (98%). | Recording by videophone at home had comparable outcomes to DOT at clinic. |
| Wade | Home videophones improve direct observation in tuberculosis: A mixed methods evaluation. | Video phone. The video recording was for a 4 month period. | Retrospective study using qualitative and quantitative approaches. 58 patients used videophone service while 70 patients were observed personally at home. The study recruited children and adults. Participant’s age ranged between 19 and 60 years. | To evaluate the feasibility and economic benefit of using video phone observation at home compared with direct clinic observation of administration of tuberculosis therapy. | Lower percentage of missed observations by the video phone group (12%) compared with 31.1% in the direct clinic observation group. Fewer staff and less time required for video phone group. | Directly observing TB patients via video phone was more effective than directly observing them in the clinic, and led to cost savings. The video phone service was associated with more flexibility, patient acceptability and efficiency in relation to healthcare professional time. |
| Hoffman | Mobile direct observation treatment for tuberculosis patients: A technical feasibility pilot using mobile phones in Nairobi, Kenya. | Mobile phone. | Pilot study involved | To study the feasibility of observing TB patient administering medication remotely via the mobile DOT approach. | All participants completed the study. 8 patients preferred to use mobile phone rather than coming to hospital for observation. | MDOT observation was feasible and the approach was satisfactory for the majority of participants. |
| Krueger | Videophone utilization as an alternative to direct observation therapy. | Videophone. Recording was for an average of 20 weeks. | Retrospective study covering period between 2002–2006. | To assess cost effectiveness of the videophone as an option for performing DOT approach in TB patients. | The rate of adherence with TB recorded treatment via videophone was high. A total of US $ 139, 546 was saved on the cost of transport and healthcare provider observation time. | Videophone observation for treatment was a valid method and can be used to improve adherence. |
| Wade | Videophone delivery of Medication Management in Community Nursing | Video phone. Study was carried out for 6 months. | Pilot study recruited 9 TB patients with mild cognitive/ impairment. | To evaluate the usability and potential use of videophone to remotely observe TB therapy administration at the patients’ homes. | Positive attitude recorded toward use of this technology from patients and staff. It is useful for saving time and costs related to home visiting. | Videophone provides an efficient alternative approach to assess therapy at the patient’s home instead of visiting the patient’s home. 6 (67%) patients would like to continue use of the mobile technology. |
| Smith | Tele-health home monitoring of solitary persons with mild dementia | Videophone. This study was carried out with patients for an average of 6 months. | Compared video phone monitoring group (8 patients) with a control group (6 patients). Age of participants range (79–85 years). | To assess technical feasibility of the approach, medication administration and mood in patients with dementia. | The technical success of using the videophone was 82%. Video phone adherence was 81%, while adherence was only 66% in control patients. | Telemonitoring of patient treatment via videophone led to maintaining dementia patients’ adherence, but there was no clear influence on patient mood. |
| Demaio | The application of telemedicine technology to observed therapy programme for tuberculosis: A pilot project | Videophone system was connected with touch phone or television. Study duration was not mentioned. | Pilot study using videophone to connect between patients’ homes and healthcare centre for treatment observation. Six patients used DOT method then switched to using the videophone method. | To assess the use of video phone for direct observation of TB patient medicine administration and compare this with DOT method. | The recorded rate of videophone adherence was 95% while it was 97% for direct observation at the clinic. The average time for video phone observation was 3 minutes, while direct observation at the clinic needed one hour. | Videophone can lead to sustainable adherence and can be a cost effective approach. |
DOT = Direct Observation of Therapy
Benefits and implementation barriers of using MDOT compared with standard DOT at home or in the clinic.
DOT = Direct Observation of Therapy
MDOT = Mobile Direct Observation of Therapy
Ongoing or planned clinical trials using the MDOT approach in assessing treatment administration (information obtained from ClinicalTrial.gov website, accessed on Feb 2016).
| Lead researcher | Clinical trial title | Study design | Participants | Intervention | Starting date | Estimated study completion date |
|---|---|---|---|---|---|---|
| Richard Garfeine | Video directly observed therapy (VDOT) for monitoring adherence to latent tuberculosis treatment (LTBI) | Randomised parallel assignment study where video arm compared with attending in-person arm. | Participant age for recruitment: 13 years and older. | Application for smartphone that enables tuberculosis ( | January 2016 | December 2019 |
| Daniel Labovitz, Montefiore Medical Center (USA) | Using artificial intelligence to measure and optimise adherence in patients on | Randomised | Participant age for recruitment: | Mobile App to be downloaded onto a smart- phone. Artificial intelligence and visual recognition technology to be used to verify medication ingestion. | March 2015 | March 2016 |
| Susan Creary, | Electronic hydroxyurea adherence: a strategy to improve hydroxyurea adherence in patients with | This is a non-randomised | Children and adults to be recruited. | MDOT based on patients' smartphones. Electronic reminder alerts sent to patients. Video recording of patients' daily hydroxyurea administration | July 2014 | December 2017 |
| Not provided (Moldova) | Virtually observed treatment (VOT) for tuberculosis in Moldova | Randomised | Participants: age ˃18 years old | October 2015 | February 2017 | |
| Anthony DeFulio, | SteadyRx: smartphone ART adherence intervention for drug users | Randomised | Participants aged 18 to 65 years old. | Mobile App will automatically facilitate consultation of human immunodeficiency virus ( | Not specified | February 2017 |
| Alain Litwin, Montefiore Medical Center | Using artificial intelligence to monitor medication adherence in opioid replacement therapy | Single group assignment | Participants aged ˃18 years old | This study will use an artificial intelligence platform via mobile app to automatically confirm medication ingestion of opioid dependence. In case of missed dose, an alert message will be sent via text message or Email. | March 2016 | March 2017 |
Demographics of participating children, MDOT adherence rate and the mobile devices used in the feasibility study.
| Patient | Parent ID | Child gender | Parent gender | Age of child (years) | No. of uploaded videos | No. of days missed at least 1 video | Mobile DOT adherence % | Device brand used for MDOT |
|---|---|---|---|---|---|---|---|---|
| C1 | P1 | F | F | 11 | 26 | 1 | 92.8 | ipad (Apple) |
| C2 | P1 | F | F | 5 | 25 | 2 | 89.2 | ipad (Apple) |
| C3 | P3 | M | F | 7 | 11 | 9 | 39.2 | Iphone(Apple) |
| C4 | P4 | F | F | 5 | 24 | 2 | 85.7 | HTC phone (Android) |
| C5 | P5 | F | F | 6 | 24 | 2 | 85.7 | iphone(Apple) |
| C6 | P5 | F | F | 2 | 24 | 2 | 85.7 | Ipad (Apple) |
| C7 | P7 | F | F | 6 | 22 | 3 | 78.5 | Iphone (Apple) |
| C8 | P8 | M | F | 3 | 22 | 3 | 78.5 | Iphone (Apple) |
| C9 | P9 | M | M | 10 | 28 | 0 | 100 | Hudl tablet (Android) |
| C10 | P10 | F | F | 8 | 27 | 1 | 96.4 | Huawei Tablet (Android) |
| C11 | P10 | F | F | 10 | 28 | 0 | 100 | Huawei Tablet (Android) |
| C12 | P12 | M | F | 12 | 23 | 3 | 89.28 | iphone (Apple) |
MDOT = Mobile Direct Observation of Therapy
Fig 2Mobile DOT video upload adherence in the feasibility study.
Fig 3Number of children who participated in the pilot study in children with asthma.
Classification of inhaler technique in children during the 6 week use of the MDOT approach in the pilot study in children with asthma.
| Child ID | 1st week | 2nd week | 3rd week | 4th week | 5th week | 6th week |
|---|---|---|---|---|---|---|
| DE1 | P. effective | Effective | Effective | P. effective | Effective | Effective |
| DE2 | Poor | P. effective | Effective | Effective | Effective | Effective |
| DE3 | P. effective | P. effective | Effective | Effective | ---------- | ----------- |
| DE4 | Effective | Effective | Effective | Effective | Effective | Effective |
| DE5 | P. effective | Effective | P. effective | Effective | Effective | Effective |
| DE6 | Poor | P. effective | P. effective | Effective | Effective | Effective |
| DE7 | Effective | Effective | Effective | Effective | Effective | Effective |
| DE8 | Poor | Effective | Effective | Effective | Effective | Effective |
| DE9 | Effective | Effective | Effective | Effective | Effective | Effective |
| DE10 | P. effective | P. effective | ------------ | ------------ | ---------- | ----------- |
| IM1 | P. effective | Effective | P. effective | Effective | Effective | Effective |
| IM2 | P. effective | Effective | Effective | Effective | Effective | Effective |
| IM3 | P. effective | P. effective | Effective | Effective | Effective | Effective |
| IM4 | P. effective | P. effective | Effective | P. effective | Effective | Effective |
| IM5 | Effective | P. effective | Effective | Effective | Effective | Effective |
| IM6 | Poor | ------------ | ----------- | ----------- | ---------- | ---------- |
| IM7 | P. effective | P. effective | P. effective | Effective | Effective | Effective |
| Im8 | P. effective | P. effective | Effective | Effective | Effective | Effective |
| IM9 | P. effective | P. effective | Effective | Effective | Effective | Effective |
| IM10 | P. effective | Effective | Effective | Effective | Effective | Effective |
| IM11 | P. effective | Effective | P. effective | Effective | Effective | Effective |
| IM12 | Effective | Effective | Effective | ------------- | ---------- | ----------- |
* Stopped recording and did not respond to phone or text messages
P. effective = partially effective technique
MDOT = Mobile Direct Observation of Therapy
Summary data on impact of MDOT intervention on asthma outcomes (at 12 weeks post initiation of MDOT) in the pilot study in children with asthma.
| Outcomes | Baseline | 12 weeks post MDOT | p–value |
|---|---|---|---|
| Asthma control | 13.1±5.7 | 17.8±4.3 | 0.007 |
| FeNO (PPM) | 38.7±28.8 | 19.3±14.4 | 0.019 |
| Spirometric value | 91.9±13.1 | 92.8 ± 10.5 | 0.721 |
| FEV1/FVC% | 92.6± 10.9 | 92.8±10.5 | 0.952 |
| Child QOL | 3.8±1.6 | 4.9±1.5 | 0.079 |
| Parent QOL | 3.7±1.4 | 5.4±1.3 | 0.001 |
| Clinical assessment of asthma | 0 | 7 | - |
| Partly controlled | 8 | 11 | - |
| Uncontrolled | 14 | 4 | - |
Independent T test (Significant at p<0.05)
MDOT = Mobile Direct Observation of Therapy